AZD-2207
AZD-2207 is a cannabinoid receptor CB1 antagonist and highly lipophilic compound for the treatment of type 2 diabetes mellitus and obesity.
For research use only. We do not sell to patients.
Chemical Information
| Name | AZD-2207 |
|---|---|
| Iupac Chemical Name | 1-Propanesulfonic acid, 3,3,3-trifluoro-, 4-(2-(2,4-dichlorophenyl)-5-methyl-4-((1-piperidinylamino)carbonyl)-1H-imidazol-1-yl)phenyl ester |
| Synonyms | AZD-2207; AZD2207; AZD 2207 |
| Molecular Formula | C25H25Cl2F3N4O4S |
| Molecular Weight | 605.46 |
| Smile | Cc1c(nc(c2ccc(Cl)cc2Cl)n1c3ccc(OS(=O)(=O)CCC(F)(F)F)cc3)C(=O)NN4CCCCC4 |
| InChiKey | NHIXRYPUVCFFAF-UHFFFAOYSA-N |
| InChi | InChI=1S/C25H25Cl2F3N4O4S/c1-16-22(24(35)32-33-12-3-2-4-13-33)31-23(20-10-5-17(26)15-21(20)27)34(16)18-6-8-19(9-7-18)38-39(36,37)14-11-25(28,29)30/h5-10,15H,2-4,11-14H2,1H3,(H,32,35) |
| CAS Number | 866598-45-0 |
| Related CAS |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Solid powder |
|---|---|
| Purity | 98% Min. |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1. Tannergren C, Karlsson E, Sigfridsson K, Lindfors L, Ku A, Polentarutti B, Carlert S. Biopharmaceutic Profiling of Salts to Improve Absorption of Poorly Soluble Basic Drugs. J Pharm Sci. 2016 Nov;105(11):3314-3323. doi: 10.1016/j.xphs.2016.07.016. Epub 2016 Sep 13. PMID: 27637320.
2. Kourentas A, Vertzoni M, Barmpatsalou V, Augustijns P, Beato S, Butler J, Holm R, Ouwerkerk N, Rosenberg J, Tajiri T, Tannergren C, Symillides M, Reppas C. The BioGIT System: a Valuable In Vitro Tool to Assess the Impact of Dose and Formulation on Early Exposure to Low Solubility Drugs After Oral Administration. AAPS J. 2018 May 24;20(4):71. doi: 10.1208/s12248-018-0231-8. PMID: 29797293.
Chemical Structure
